QTTB Earnings Date: Nov 12, 2026 (Estimated) — Q32 Bio Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is QTTB's next earnings date?
Q32 Bio Inc. (QTTB) is expected to report Q3 2026 earnings on Thursday, November 12, 2026 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.36.
How did QTTB do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), Q32 Bio Inc. posted EPS of -$0.44 versus the -$0.53 estimate, a beat of 21.4%. Revenue was $0 against a $1.0M estimate. The stock's 1-day post-earnings move was +2.1%.
How much does QTTB stock move after earnings?
QTTB beat EPS estimates in 5 of its last 7 reported quarters. Over the last 7 reports the stock moved an average of 5.9% (up or down) in the day after earnings.
About Q32 Bio Inc.
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | -0.53 | -0.44 | +21.43% | $0 | ✅ Beat | +2.07% | -4.61% | -15.88% |
| 2026-05-05 | Q1 2026 | -0.65 | -0.54 | +16.92% | $0 | ✅ Beat | +1.98% | +2.78% | +141.87% |
| 2026-03-10 | Q4 2025 | -0.85 | 3.65 | +529.41% | $53.7M | ✅ Beat | +17.45% | +23.53% | +7.25% |
| 2025-11-13 | Q3 2025 | -1.27 | -0.60 | +52.76% | $0 | ✅ Beat | -9.05% | -12.76% | +21.81% |
| 2025-08-06 | Q2 2025 | -1.14 | -0.78 | +31.58% | $0 | ✅ Beat | -1.52% | -15.15% | -16.16% |
| 2025-03-11 | Q4 2024 | — | -1.16 | — | $0 | — | -7.77% | +6.31% | -29.61% |
| 2024-11-07 | Q3 2024 | -1.40 | -1.46 | -4.29% | $0 | ❌ Miss | -1.13% | -17.23% | -46.00% |
| 2022-12-29 | -8.86 | -10.74 | — | $802,000 | ❌ Miss | — | — | — |
Showing last 8 quarters.